Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Syros Pharmaceuticals, Inc. SYRS
$3.44
+$0.13 (3.70%)
На 18:00, 12 мая 2023
+772.09%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
69492986.00000000
-
week52high
11.50
-
week52low
2.42
-
Revenue
14880000
-
P/E TTM
0
-
Beta
1.66297500
-
EPS
-7.04000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | Outperform | 10 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 12 июл 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 17 мая 2022 г. |
| Alliance Global Partners | Buy | Buy | 17 мая 2022 г. |
| Roth Capital | Buy | Buy | 23 сент 2021 г. |
| Oppenheimer | Outperform | Outperform | 15 ноя 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 15 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 15 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Quirk Gerald E | A | 45000 | 45000 | 11 окт 2022 г. |
| Chee Conley | A | 34000 | 34000 | 06 окт 2022 г. |
| Chee Conley | A | 44500 | 44500 | 06 окт 2022 г. |
| Simonian Nancy A | A | 80250 | 80250 | 06 окт 2022 г. |
| Simonian Nancy A | A | 115000 | 115000 | 06 окт 2022 г. |
| Haas Jason | A | 37750 | 37750 | 06 окт 2022 г. |
| Haas Jason | A | 49750 | 49750 | 06 окт 2022 г. |
| Roth David | A | 37750 | 37750 | 06 окт 2022 г. |
| Roth David | A | 49750 | 49750 | 06 окт 2022 г. |
| Olson Eric R | A | 34000 | 34000 | 06 окт 2022 г. |
Новостная лента
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
Business Wire
03 мая 2023 г. в 07:30
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its first quarter 2023 financial results and provide a corporate update. To access the live conference call, please dial (888) 886-7786 (domestic) or (416) 764-8658 (internati.
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
02 мар 2023 г. в 11:18
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Syros: Multiple Shots On Goal In Blood Cancer Space
Seeking Alpha
08 февр 2023 г. в 10:10
Final results from pivotal study SELECT-MDS-1, using Tamibarotene for the treatment of patients with newly diagnosed high-risk MDS that have RARA gene overexpression, expected Q3 of 2024. The global myelodysplastic syndrome market is expected to reach $5.6 billion by 2032; 50% of high-risk MDS patients have RARA expression.
Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength?
Zacks Investment Research
01 февр 2023 г. в 11:18
Syros Pharmaceuticals, Inc. (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Syros Pharmaceuticals A Buy Given Stock Price And Pipeline Potential (Rating Upgrade)
Seeking Alpha
15 янв 2023 г. в 01:52
Syros Pharmaceuticals is developing cancer therapies. Its most advanced potential therapy is tamibarotene for MDS.